Skip to main content

You are here

Vishnu Chaturvedi, Ph.D.

Vishnu Chaturvedi, Ph.D.

Director, Mycology Special Services
Ph.D., University of Delhi, Delhi, India
Postdoctoral training: Texas Tech University Health Sciences Center, Lubbock, TX
Postdoctoral training: University of Cincinnati School of Medicine, Cincinnati, OH

Research Interests

Genomics – We are working on the whole-genome sequencing (WGS) methods for a number of fungal pathogens. The approaches are based on short-read (Illumina) and long-read (PacBio and Oxford Nanopore) sequencing technologies. The corresponding bioinformatics workflow is also being modified. The long-term goal is to validate and implement CLIA-compliant WGS applications for a medical mycology laboratory.

Molecular epidemiology – We use molecular epidemiology tools for rapid outbreak investigations, characterization of unknown etiologic agents and correlation of geography with pathogen virulence. We aim to successfully bridge the gap between basic research and translational science for improved infectious disease diagnosis.

Microbial Pathogenic Mechanisms - We pioneered the use of genetic and genomic approaches to dissect pathogenic mechanisms used by human and bat white-nose syndrome fungal pathogens. Our focus remains on the exquisite interplay of fungal stress response, metabolic profiles, and virulence.

Antimicrobial standardization & discovery – Collaborative research has resulted in development of several rapid and sensitive methods for susceptibility testing of antifungals alone and in combination. In addition, Candida and Cryptococcus prolyl isomerases were identified as unique antifungal drug targets. Our current focus is on the WGS-enabled testing for antimicrobial resistance in emerging multidrug-resistant pathogen Candida auris.

Select Publications

Yan L, Xia K, Yu Y, Miliakos A, Chaturvedi S, Zhang F, Chen S, Chaturvedi V, Linhardt RJ.
Unique cell surface mannan of yeast pathogen Candida auris with selective binding to IgG.
ACS Infect Dis.
DOI: doi:10.1021/acsinfecdis.9b00450
Ostrowsky B, Greenko J, Adams E, Quinn M, O'Brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, Lutterloh E, Blog D; C. auris Investigation Work Group.
Candida auris Isolates Resistant to Three Classes of Antifungal Medications - New York, 2019.
MMWR Morb Mortal Wkly Rep.
DOI: doi: 10.15585/mmwr.mm6901a2
Zhu Y, O'Brien B, Leach L, Clarke A, Bates M, Adams E, Ostrowsky B, Quinn M,Dufort E, Southwick K, Erazo R, Haley VB, Bucher C, Chaturvedi V, Limberger RJ, Blog D, Lutterloh E, Chaturvedi S.
Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned.
J Clin Microbiol.
DOI: doi: 10.1128/JCM.01503-19
O'Brien B, Chaturvedi S, Chaturvedi V.
In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.
Antimicrob Agents Chemother.
DOI: doi: 10.1128/AAC.02195-19
Leach L, Russell A, Zhu Y, Chaturvedi S, Chaturvedi V.
A Rapid and Automated Sample-to-Result Candida auris Real-Time PCR Assay for High-Throughput Testing of Surveillance Samples with the BD Max Open System.
J Clin Microbiol.
DOI: doi: 10.1128/JCM.00630-19